MatchMedi
한국어

Options mapped

Non-melanoma skin cancer (BCC / cSCC): options by country

Sourced options by country plus visit-prep questions for Non-melanoma skin cancer (BCC / cSCC). Each line links to its regulator, HTA, or guideline source. This page maps options; it does not recommend or rank them.

Options mappedSolid tumorLast checked June 2026

What this page does

Maps options by country

It maps sourced options by country alongside diagnosis wording, stage, test results, specialists, and trial-search terms.

What it does not do

Does not choose treatment

It does not rank treatments, recommend a choice, or decide clinical fit.

Where it comes from

Built on trusted sources

Every option links to a trusted regulator, HTA, or guideline source, and the list grows as new sources pass verification.

Information to gather before the next visit

  • Is the cSCC locally advanced, recurrent/metastatic, or post-surgery/radiation high-risk?
  • Is curative surgery or curative radiation considered unsuitable?
  • Which PD-1 inhibitor is approved, accessible, and appropriate in the treating setting?
  • Is curative surgery or radiation unsuitable, or is this an adjuvant post-surgery/radiation high-risk setting?

Trial-search terms to discuss

Non-melanoma skin cancer (BCC / cSCC) clinical trial

Options by country

Treatments by country

Regulatory and access status by country, from official sources. It shows what exists and where — not a recommendation.

United States

  • Surgery; radiation therapy; vismodegib (Erivedge); sonidegib (Odomzo); cemiplimab-rwlc (Libtayo)[1]FDA-approvedHedgehog pathway inhibition treatment context; no mutation biomarker required by fetched sources; Locally advanced or metastatic BCC; advanced BCC where surgery/radiation may not be appropriate; BCC after hedgehog pathway inhibitor treatment or when HHI is not appropriate. · NCI PDQ is an evidence summary, not a payer source. FDA approval notice does not determine individual eligibility, sequencing, tolerability, or reimbursement. Sonidegib and vismodegib indications differ and require label-level confirmation for exact use. Confidence/conflicts: High for U.S. framework and FDA cemiplimab approval; exact HHI label wording and payer access remain follow-up gaps.
  • Surgery; radiation therapy; vismodegib (Erivedge); sonidegib (Odomzo); cemiplimab-rwlc (Libtayo)[1]FDA-approvedHedgehog pathway inhibition treatment context; no mutation biomarker required by fetched sources; Locally advanced or metastatic BCC; advanced BCC where surgery/radiation may not be appropriate; BCC after hedgehog pathway inhibitor treatment or when HHI is not appropriate. · NCI PDQ is an evidence summary, not a payer source. FDA approval notice does not determine individual eligibility, sequencing, tolerability, or reimbursement. Sonidegib and vismodegib indications differ and require label-level confirmation for exact use. Confidence/conflicts: High for U.S. framework and FDA cemiplimab approval; exact HHI label wording and payer access remain follow-up gaps.
  • Surgery; radiation therapy; vismodegib (Erivedge); sonidegib (Odomzo); cemiplimab-rwlc (Libtayo)[1]FDA-approvedHedgehog pathway inhibition treatment context; no mutation biomarker required by fetched sources; Locally advanced or metastatic BCC; advanced BCC where surgery/radiation may not be appropriate; BCC after hedgehog pathway inhibitor treatment or when HHI is not appropriate. · NCI PDQ is an evidence summary, not a payer source. FDA approval notice does not determine individual eligibility, sequencing, tolerability, or reimbursement. Sonidegib and vismodegib indications differ and require label-level confirmation for exact use. Confidence/conflicts: High for U.S. framework and FDA cemiplimab approval; exact HHI label wording and payer access remain follow-up gaps.
  • Surgery; radiation therapy; vismodegib (Erivedge); sonidegib (Odomzo); cemiplimab-rwlc (Libtayo)[1]FDA-approvedHedgehog pathway inhibition treatment context; no mutation biomarker required by fetched sources; Locally advanced or metastatic BCC; advanced BCC where surgery/radiation may not be appropriate; BCC after hedgehog pathway inhibitor treatment or when HHI is not appropriate. · NCI PDQ is an evidence summary, not a payer source. FDA approval notice does not determine individual eligibility, sequencing, tolerability, or reimbursement. Sonidegib and vismodegib indications differ and require label-level confirmation for exact use. Confidence/conflicts: High for U.S. framework and FDA cemiplimab approval; exact HHI label wording and payer access remain follow-up gaps.

European Union

  • Cemiplimab (Libtayo)[2]EMA authorisedNo biomarker requirement stated in fetched EMA page; Adult metastatic or locally advanced cSCC not candidates for curative surgery/radiation; adult high-risk recurrence after surgery and radiation adjuvant setting. · EMA central authorization does not establish reimbursement or access in Germany, France, or other member states. No claim is made for pembrolizumab EU cSCC status from fetched sources. Confidence/conflicts: High for EMA authorization text; member-state reimbursement remains a gap.
  • Cemiplimab (Libtayo)[2]EMA authorisedNo biomarker requirement stated in fetched EMA page; Adult metastatic or locally advanced cSCC not candidates for curative surgery/radiation; adult high-risk recurrence after surgery and radiation adjuvant setting. · EMA central authorization does not establish reimbursement or access in Germany, France, or other member states. No claim is made for pembrolizumab EU cSCC status from fetched sources. Confidence/conflicts: High for EMA authorization text; member-state reimbursement remains a gap.

United Kingdom

  • Cemiplimab (Libtayo)[3]ApprovedNo biomarker requirement stated in fetched NICE recommendation; Adults with metastatic or locally advanced cSCC when curative surgery or curative radiotherapy is not suitable. · NICE recommendation is England/Wales NHS appraisal context and includes stopping and commercial-arrangement conditions. It does not establish Scotland/Northern Ireland status or MHRA label specifics. Confidence/conflicts: High for NICE recommendation text; devolved UK status and MHRA label specifics remain gaps.
  • Cemiplimab (Libtayo)[3]ApprovedNo biomarker requirement stated in fetched NICE recommendation; Adults with metastatic or locally advanced cSCC when curative surgery or curative radiotherapy is not suitable. · NICE recommendation is England/Wales NHS appraisal context and includes stopping and commercial-arrangement conditions. It does not establish Scotland/Northern Ireland status or MHRA label specifics. Confidence/conflicts: High for NICE recommendation text; devolved UK status and MHRA label specifics remain gaps.
  • Vismodegib (Erivedge); best supportive care comparator context[4]ApprovedNo biomarker requirement stated in fetched NICE recommendation; Symptomatic metastatic BCC; locally advanced BCC inappropriate for surgery or radiotherapy in adults. · This is a negative NICE recommendation in England/Wales context, not an MHRA label denial. It does not establish Scotland/Northern Ireland status, private access, or later appraisals of cemiplimab/sonidegib. Existing patients started before guidance publication may have different funding arrangements as NICE states. Confidence/conflicts: High for NICE vismodegib non-recommendation; UK cemiplimab/sonidegib status remains active gap.
  • Vismodegib (Erivedge); best supportive care comparator context[4]ApprovedNo biomarker requirement stated in fetched NICE recommendation; Symptomatic metastatic BCC; locally advanced BCC inappropriate for surgery or radiotherapy in adults. · This is a negative NICE recommendation in England/Wales context, not an MHRA label denial. It does not establish Scotland/Northern Ireland status, private access, or later appraisals of cemiplimab/sonidegib. Existing patients started before guidance publication may have different funding arrangements as NICE states. Confidence/conflicts: High for NICE vismodegib non-recommendation; UK cemiplimab/sonidegib status remains active gap.

Sources

  1. National Cancer Institute (NCI) — national cancer agency news / FDA approval context · national cancer agency news / FDA approval context
  2. European Medicines Agency (EMA) — regulator EPAR · regulator EPAR
  3. NICE — technology appraisal recommendation · technology appraisal recommendation
  4. NICE — technology appraisal recommendation · technology appraisal recommendation

This is official regulatory and access status only — not medical advice, not a recommendation, and not a statement about eligibility. Whether any option fits depends on your situation and your oncology team. Status changes over time; confirm the current position with the linked source. Last checked 2026-06-12.

Beyond approved care

In clinical trials & emerging options

Options that are not — or not yet — an approved standard where you live: studies, clinical trials, off-label use, and early evidence that your own oncologist may not raise. Each is labeled by how strong the evidence is. A listing here is information to research and discuss with your team; it does not mean a treatment is proven, safe for you, or available today.

In clinical trials

  • Cemiplimab-rwlc (Libtayo); pembrolizumab (Keytruda); surgery; radiation therapy; clinical trialsClinical trialClinical trialInvestigationalUnited States · No biomarker requirement stated in fetched sources; PD-1 inhibitor class is treatment mechanism; Recurrent or metastatic cSCC not amenable to curative surgery or radiation; locally advanced cSCC not amenable to curative surgery; adjuvant treatment after surgery and radiation for high-risk recurrence. · NCI PDQ is an evidence summary, not a payer source. FDA approval notices do not determine eligibility, toxicity suitability, or reimbursement. Adjuvant cemiplimab applies only to the high-risk post-surgery/radiation context described by FDA. Confidence/conflicts: High for U.S. evidence summary and approval notices; payer and sequencing details remain unverified. U.S. Food and Drug Administration (FDA) — regulator approval notice
  • Cemiplimab-rwlc (Libtayo); pembrolizumab (Keytruda); surgery; radiation therapy; clinical trialsClinical trialClinical trialInvestigationalUnited States · No biomarker requirement stated in fetched sources; PD-1 inhibitor class is treatment mechanism; Recurrent or metastatic cSCC not amenable to curative surgery or radiation; locally advanced cSCC not amenable to curative surgery; adjuvant treatment after surgery and radiation for high-risk recurrence. · NCI PDQ is an evidence summary, not a payer source. FDA approval notices do not determine eligibility, toxicity suitability, or reimbursement. Adjuvant cemiplimab applies only to the high-risk post-surgery/radiation context described by FDA. Confidence/conflicts: High for U.S. evidence summary and approval notices; payer and sequencing details remain unverified. U.S. Food and Drug Administration (FDA) — regulator approval notice
  • Cemiplimab-rwlc (Libtayo); pembrolizumab (Keytruda); surgery; radiation therapy; clinical trialsClinical trialClinical trialInvestigationalUnited States · No biomarker requirement stated in fetched sources; PD-1 inhibitor class is treatment mechanism; Recurrent or metastatic cSCC not amenable to curative surgery or radiation; locally advanced cSCC not amenable to curative surgery; adjuvant treatment after surgery and radiation for high-risk recurrence. · NCI PDQ is an evidence summary, not a payer source. FDA approval notices do not determine eligibility, toxicity suitability, or reimbursement. Adjuvant cemiplimab applies only to the high-risk post-surgery/radiation context described by FDA. Confidence/conflicts: High for U.S. evidence summary and approval notices; payer and sequencing details remain unverified. U.S. Food and Drug Administration (FDA) — regulator approval notice
  • Cemiplimab-rwlc (Libtayo); pembrolizumab (Keytruda); surgery; radiation therapy; clinical trialsClinical trialClinical trialInvestigationalUnited States · No biomarker requirement stated in fetched sources; PD-1 inhibitor class is treatment mechanism; Recurrent or metastatic cSCC not amenable to curative surgery or radiation; locally advanced cSCC not amenable to curative surgery; adjuvant treatment after surgery and radiation for high-risk recurrence. · NCI PDQ is an evidence summary, not a payer source. FDA approval notices do not determine eligibility, toxicity suitability, or reimbursement. Adjuvant cemiplimab applies only to the high-risk post-surgery/radiation context described by FDA. Confidence/conflicts: High for U.S. evidence summary and approval notices; payer and sequencing details remain unverified. U.S. Food and Drug Administration (FDA) — regulator approval notice
  • Cemiplimab-rwlc (Libtayo); pembrolizumab (Keytruda); surgery; radiation therapy; clinical trialsClinical trialClinical trialInvestigationalUnited States · No biomarker requirement stated in fetched sources; PD-1 inhibitor class is treatment mechanism; Recurrent or metastatic cSCC not amenable to curative surgery or radiation; locally advanced cSCC not amenable to curative surgery; adjuvant treatment after surgery and radiation for high-risk recurrence. · NCI PDQ is an evidence summary, not a payer source. FDA approval notices do not determine eligibility, toxicity suitability, or reimbursement. Adjuvant cemiplimab applies only to the high-risk post-surgery/radiation context described by FDA. Confidence/conflicts: High for U.S. evidence summary and approval notices; payer and sequencing details remain unverified. U.S. Food and Drug Administration (FDA) — regulator approval notice
  • Cemiplimab; pembrolizumab plus berahyaluronidase alfa; INCB099280; AZD6750 plus rilvegostomigClinical trial · NCT03969004Clinical trialTrial only (registry)Japan · No biomarker requirement stated for the cSCC-specific Japan records; broad solid-tumor studies may have protocol-specific requirements; High-risk cSCC after surgery and radiation; recurrent/metastatic cSCC; locally advanced unresectable cSCC; advanced/metastatic solid-tumor cohorts including skin SCC. · Registry records do not establish PMDA approval, reimbursement, routine access, or individual eligibility. Some studies are active-not-recruiting or completed. Broad solid-tumor cohorts do not prove cSCC-specific enrollment at every site. Confidence/conflicts: High for Japan registry-listed cSCC activity; PMDA/routine access unverified. ClinicalTrials.gov — clinical-trial registry
  • Cemiplimab; pembrolizumab plus berahyaluronidase alfa; INCB099280; AZD6750 plus rilvegostomigClinical trial · NCT03969004Clinical trialTrial only (registry)Japan · No biomarker requirement stated for the cSCC-specific Japan records; broad solid-tumor studies may have protocol-specific requirements; High-risk cSCC after surgery and radiation; recurrent/metastatic cSCC; locally advanced unresectable cSCC; advanced/metastatic solid-tumor cohorts including skin SCC. · Registry records do not establish PMDA approval, reimbursement, routine access, or individual eligibility. Some studies are active-not-recruiting or completed. Broad solid-tumor cohorts do not prove cSCC-specific enrollment at every site. Confidence/conflicts: High for Japan registry-listed cSCC activity; PMDA/routine access unverified. ClinicalTrials.gov — clinical-trial registry
  • Cemiplimab; pembrolizumab plus berahyaluronidase alfa; INCB099280; AZD6750 plus rilvegostomigClinical trial · NCT03969004Clinical trialTrial only (registry)Japan · No biomarker requirement stated for the cSCC-specific Japan records; broad solid-tumor studies may have protocol-specific requirements; High-risk cSCC after surgery and radiation; recurrent/metastatic cSCC; locally advanced unresectable cSCC; advanced/metastatic solid-tumor cohorts including skin SCC. · Registry records do not establish PMDA approval, reimbursement, routine access, or individual eligibility. Some studies are active-not-recruiting or completed. Broad solid-tumor cohorts do not prove cSCC-specific enrollment at every site. Confidence/conflicts: High for Japan registry-listed cSCC activity; PMDA/routine access unverified. ClinicalTrials.gov — clinical-trial registry
  • Er:YAG ablative fractional laser-assisted photodynamic therapy; MAL-PDT; MDNA11 plus pembrolizumabClinical trial · NCT02018679Clinical trialTrial only (registry)Korea · MSI-H, dMMR, or high tumor mutational burden may apply to some broad IL-2 study cohorts; no mutation biomarker required by fetched nodular BCC PDT record; Nodular BCC local therapy study; advanced/unresectable solid tumor cohort including BCC. · Registry records do not establish MFDS approval, reimbursement, routine access, or individual eligibility. The MDNA11 record is broad and does not prove BCC-specific enrollment at every South Korea site. Confidence/conflicts: Medium-high for Korea registry-listed BCC activity; regulator/access unverified. ClinicalTrials.gov — clinical-trial registry
  • Er:YAG ablative fractional laser-assisted photodynamic therapy; MAL-PDT; MDNA11 plus pembrolizumabClinical trial · NCT02018679Clinical trialTrial only (registry)Korea · MSI-H, dMMR, or high tumor mutational burden may apply to some broad IL-2 study cohorts; no mutation biomarker required by fetched nodular BCC PDT record; Nodular BCC local therapy study; advanced/unresectable solid tumor cohort including BCC. · Registry records do not establish MFDS approval, reimbursement, routine access, or individual eligibility. The MDNA11 record is broad and does not prove BCC-specific enrollment at every South Korea site. Confidence/conflicts: Medium-high for Korea registry-listed BCC activity; regulator/access unverified. ClinicalTrials.gov — clinical-trial registry
  • Er:YAG ablative fractional laser-assisted photodynamic therapy; MAL-PDT; MDNA11 plus pembrolizumabClinical trial · NCT02018679Clinical trialTrial only (registry)Korea · MSI-H, dMMR, or high tumor mutational burden may apply to some broad IL-2 study cohorts; no mutation biomarker required by fetched nodular BCC PDT record; Nodular BCC local therapy study; advanced/unresectable solid tumor cohort including BCC. · Registry records do not establish MFDS approval, reimbursement, routine access, or individual eligibility. The MDNA11 record is broad and does not prove BCC-specific enrollment at every South Korea site. Confidence/conflicts: Medium-high for Korea registry-listed BCC activity; regulator/access unverified. ClinicalTrials.gov — clinical-trial registry
  • Er:YAG ablative fractional laser-assisted photodynamic therapy; MAL-PDT; MDNA11 plus pembrolizumabClinical trial · NCT02018679Clinical trialTrial only (registry)Korea · MSI-H, dMMR, or high tumor mutational burden may apply to some broad IL-2 study cohorts; no mutation biomarker required by fetched nodular BCC PDT record; Nodular BCC local therapy study; advanced/unresectable solid tumor cohort including BCC. · Registry records do not establish MFDS approval, reimbursement, routine access, or individual eligibility. The MDNA11 record is broad and does not prove BCC-specific enrollment at every South Korea site. Confidence/conflicts: Medium-high for Korea registry-listed BCC activity; regulator/access unverified. ClinicalTrials.gov — clinical-trial registry
  • INCB099280; HMBD-001 plus cetuximab with or without docetaxel; sigvotatug vedotin with pembrolizumab and platinum chemotherapy; AZD6750 plus rilvegostomig; TBio-6517 plus pembrolizumab; TransCon TLR7/8 agonist with or without pembrolizumabClinical trial · NCT05888844Clinical trialTrial only (registry)Korea · No biomarker requirement stated for cSCC-specific INCB099280 and HMBD-001 records; broad cohorts may have protocol-specific criteria; Advanced cSCC; advanced/metastatic squamous cancer including cSCC; advanced solid tumors including cSCC; neoadjuvant cSCC context in a terminated study. · Registry records do not establish MFDS approval, reimbursement, routine access, or individual eligibility. Some studies are terminated or active-not-recruiting, and broad cohort studies require confirmation that the cSCC cohort is open locally. Confidence/conflicts: High for Korea registry-listed cSCC study activity; regulator/access status unverified. ClinicalTrials.gov — clinical-trial registry
  • INCB099280; HMBD-001 plus cetuximab with or without docetaxel; sigvotatug vedotin with pembrolizumab and platinum chemotherapy; AZD6750 plus rilvegostomig; TBio-6517 plus pembrolizumab; TransCon TLR7/8 agonist with or without pembrolizumabClinical trial · NCT05888844Clinical trialTrial only (registry)Korea · No biomarker requirement stated for cSCC-specific INCB099280 and HMBD-001 records; broad cohorts may have protocol-specific criteria; Advanced cSCC; advanced/metastatic squamous cancer including cSCC; advanced solid tumors including cSCC; neoadjuvant cSCC context in a terminated study. · Registry records do not establish MFDS approval, reimbursement, routine access, or individual eligibility. Some studies are terminated or active-not-recruiting, and broad cohort studies require confirmation that the cSCC cohort is open locally. Confidence/conflicts: High for Korea registry-listed cSCC study activity; regulator/access status unverified. ClinicalTrials.gov — clinical-trial registry
  • INCB099280; HMBD-001 plus cetuximab with or without docetaxel; sigvotatug vedotin with pembrolizumab and platinum chemotherapy; AZD6750 plus rilvegostomig; TBio-6517 plus pembrolizumab; TransCon TLR7/8 agonist with or without pembrolizumabClinical trial · NCT05888844Clinical trialTrial only (registry)Korea · No biomarker requirement stated for cSCC-specific INCB099280 and HMBD-001 records; broad cohorts may have protocol-specific criteria; Advanced cSCC; advanced/metastatic squamous cancer including cSCC; advanced solid tumors including cSCC; neoadjuvant cSCC context in a terminated study. · Registry records do not establish MFDS approval, reimbursement, routine access, or individual eligibility. Some studies are terminated or active-not-recruiting, and broad cohort studies require confirmation that the cSCC cohort is open locally. Confidence/conflicts: High for Korea registry-listed cSCC study activity; regulator/access status unverified. ClinicalTrials.gov — clinical-trial registry
  • INCB099280; HMBD-001 plus cetuximab with or without docetaxel; sigvotatug vedotin with pembrolizumab and platinum chemotherapy; AZD6750 plus rilvegostomig; TBio-6517 plus pembrolizumab; TransCon TLR7/8 agonist with or without pembrolizumabClinical trial · NCT05888844Clinical trialTrial only (registry)Korea · No biomarker requirement stated for cSCC-specific INCB099280 and HMBD-001 records; broad cohorts may have protocol-specific criteria; Advanced cSCC; advanced/metastatic squamous cancer including cSCC; advanced solid tumors including cSCC; neoadjuvant cSCC context in a terminated study. · Registry records do not establish MFDS approval, reimbursement, routine access, or individual eligibility. Some studies are terminated or active-not-recruiting, and broad cohort studies require confirmation that the cSCC cohort is open locally. Confidence/conflicts: High for Korea registry-listed cSCC study activity; regulator/access status unverified. ClinicalTrials.gov — clinical-trial registry
  • Pucotenlimab plus becotatug vedotin; camrelizumab plus albumin-bound paclitaxel; HLX07; IBI318; camrelizumab plus cisplatinClinical trial · NCT07394244Clinical trialTrial only (registry)China · No biomarker requirement stated in fetched China cSCC registry records; Advanced cSCC; locally advanced or metastatic cSCC; squamous cell carcinoma of skin. · Registry records do not establish NMPA approval, reimbursement, routine access, or individual eligibility. Several China records have unknown or not-yet-recruiting status despite listed site status; IBI318 record is terminated. Confidence/conflicts: High for China registry-listed cSCC study activity; NMPA/access unverified. ClinicalTrials.gov — clinical-trial registry
  • Pucotenlimab plus becotatug vedotin; camrelizumab plus albumin-bound paclitaxel; HLX07; IBI318; camrelizumab plus cisplatinClinical trial · NCT07394244Clinical trialTrial only (registry)China · No biomarker requirement stated in fetched China cSCC registry records; Advanced cSCC; locally advanced or metastatic cSCC; squamous cell carcinoma of skin. · Registry records do not establish NMPA approval, reimbursement, routine access, or individual eligibility. Several China records have unknown or not-yet-recruiting status despite listed site status; IBI318 record is terminated. Confidence/conflicts: High for China registry-listed cSCC study activity; NMPA/access unverified. ClinicalTrials.gov — clinical-trial registry
  • Pucotenlimab plus becotatug vedotin; camrelizumab plus albumin-bound paclitaxel; HLX07; IBI318; camrelizumab plus cisplatinClinical trial · NCT07394244Clinical trialTrial only (registry)China · No biomarker requirement stated in fetched China cSCC registry records; Advanced cSCC; locally advanced or metastatic cSCC; squamous cell carcinoma of skin. · Registry records do not establish NMPA approval, reimbursement, routine access, or individual eligibility. Several China records have unknown or not-yet-recruiting status despite listed site status; IBI318 record is terminated. Confidence/conflicts: High for China registry-listed cSCC study activity; NMPA/access unverified. ClinicalTrials.gov — clinical-trial registry
  • Pucotenlimab plus becotatug vedotin; camrelizumab plus albumin-bound paclitaxel; HLX07; IBI318; camrelizumab plus cisplatinClinical trial · NCT07394244Clinical trialTrial only (registry)China · No biomarker requirement stated in fetched China cSCC registry records; Advanced cSCC; locally advanced or metastatic cSCC; squamous cell carcinoma of skin. · Registry records do not establish NMPA approval, reimbursement, routine access, or individual eligibility. Several China records have unknown or not-yet-recruiting status despite listed site status; IBI318 record is terminated. Confidence/conflicts: High for China registry-listed cSCC study activity; NMPA/access unverified. ClinicalTrials.gov — clinical-trial registry
  • Sonidegib phosphate capsules; ZSP1602; ivonescimab / ivocizumabClinical trial · NCT06880848Clinical trialTrial only (registry)China · Hedgehog pathway inhibitor context for sonidegib; no mutation biomarker required by fetched China records; Adult locally advanced BCC; advanced solid tumor/BCC cohort; rare tumor cohort including BCC. · Registry records do not establish NMPA approval, reimbursement, routine access, or individual eligibility. The ZSP1602 and ivonescimab studies are broad cohorts and require protocol confirmation for BCC-specific access. Confidence/conflicts: High for China registry-listed BCC study activity; NMPA/access unverified. ClinicalTrials.gov — clinical-trial registry
  • Sonidegib phosphate capsules; ZSP1602; ivonescimab / ivocizumabClinical trial · NCT06880848Clinical trialTrial only (registry)China · Hedgehog pathway inhibitor context for sonidegib; no mutation biomarker required by fetched China records; Adult locally advanced BCC; advanced solid tumor/BCC cohort; rare tumor cohort including BCC. · Registry records do not establish NMPA approval, reimbursement, routine access, or individual eligibility. The ZSP1602 and ivonescimab studies are broad cohorts and require protocol confirmation for BCC-specific access. Confidence/conflicts: High for China registry-listed BCC study activity; NMPA/access unverified. ClinicalTrials.gov — clinical-trial registry
  • Sonidegib phosphate capsules; ZSP1602; ivonescimab / ivocizumabClinical trial · NCT06880848Clinical trialTrial only (registry)China · Hedgehog pathway inhibitor context for sonidegib; no mutation biomarker required by fetched China records; Adult locally advanced BCC; advanced solid tumor/BCC cohort; rare tumor cohort including BCC. · Registry records do not establish NMPA approval, reimbursement, routine access, or individual eligibility. The ZSP1602 and ivonescimab studies are broad cohorts and require protocol confirmation for BCC-specific access. Confidence/conflicts: High for China registry-listed BCC study activity; NMPA/access unverified. ClinicalTrials.gov — clinical-trial registry
  • Vismodegib; placebo comparatorClinical trial · NCT01815840Clinical trialTrial only (registry)Russia · Hedgehog pathway inhibitor context; no mutation biomarker required by fetched Russia registry records; Multiple BCC; locally advanced or metastatic BCC. · Registry records do not establish Russian regulator approval, reimbursement, routine access, or current availability. Both studies are completed. Confidence/conflicts: High for historical Russia registry-listed vismodegib activity; current local access unverified. ClinicalTrials.gov — clinical-trial registry
  • Vismodegib; placebo comparatorClinical trial · NCT01815840Clinical trialTrial only (registry)Russia · Hedgehog pathway inhibitor context; no mutation biomarker required by fetched Russia registry records; Multiple BCC; locally advanced or metastatic BCC. · Registry records do not establish Russian regulator approval, reimbursement, routine access, or current availability. Both studies are completed. Confidence/conflicts: High for historical Russia registry-listed vismodegib activity; current local access unverified. ClinicalTrials.gov — clinical-trial registry
  • Cosibelimab (CK-301); cemiplimab; pembrolizumab; CV8102 with or without anti-PD-1 therapyClinical trial · NCT03212404Clinical trialTrial only (registry)Thailand · No biomarker requirement stated in fetched Thailand/Russia cSCC records; Advanced cancers including cSCC; high-risk cSCC after surgery and radiation; locally advanced cSCC after surgery and radiation; intratumoral therapy context in skin SCC. · Thailand evidence is a broad advanced-cancer record and does not establish cSCC-specific enrollment at each Thai site. Russian records are registry/trial records only and do not establish Russian regulator approval, reimbursement, current enrollment, or routine access. Confidence/conflicts: Medium-high for Thailand/Russia registry activity; country approvals and active access unverified. ClinicalTrials.gov — clinical-trial registry
  • Cosibelimab (CK-301); cemiplimab; pembrolizumab; CV8102 with or without anti-PD-1 therapyClinical trial · NCT03212404Clinical trialTrial only (registry)Thailand · No biomarker requirement stated in fetched Thailand/Russia cSCC records; Advanced cancers including cSCC; high-risk cSCC after surgery and radiation; locally advanced cSCC after surgery and radiation; intratumoral therapy context in skin SCC. · Thailand evidence is a broad advanced-cancer record and does not establish cSCC-specific enrollment at each Thai site. Russian records are registry/trial records only and do not establish Russian regulator approval, reimbursement, current enrollment, or routine access. Confidence/conflicts: Medium-high for Thailand/Russia registry activity; country approvals and active access unverified. ClinicalTrials.gov — clinical-trial registry
  • Cosibelimab (CK-301); cemiplimab; pembrolizumab; CV8102 with or without anti-PD-1 therapyClinical trial · NCT03212404Clinical trialTrial only (registry)Thailand · No biomarker requirement stated in fetched Thailand/Russia cSCC records; Advanced cancers including cSCC; high-risk cSCC after surgery and radiation; locally advanced cSCC after surgery and radiation; intratumoral therapy context in skin SCC. · Thailand evidence is a broad advanced-cancer record and does not establish cSCC-specific enrollment at each Thai site. Russian records are registry/trial records only and do not establish Russian regulator approval, reimbursement, current enrollment, or routine access. Confidence/conflicts: Medium-high for Thailand/Russia registry activity; country approvals and active access unverified. ClinicalTrials.gov — clinical-trial registry

A clinical-trial listing or early report shows an option is being studied — not that it works, that it is safe for any one person, or that a site is enrolling today. Whether any of these fits is a conversation for your oncology team and the trial team. Last checked 2026-06-12.